A股異動丨天山生物(300313.SZ)跌4.77% 收到金融借款合同糾紛案的民事起訴狀和傳票
格隆匯10月22日丨天山生物(300313.SZ)跌4.77%,報21.35元,總市值67億元。

天山生物昨晚發佈公告稱,近日,公司正式收到寧波高新技術產業開發區人民法院送達的浙商銀行寧波分行與大象廣告、公司關於金融借款合同糾紛一案的民事起訴狀和傳票。
截止6月30日,公司貨幣資金餘額為1,734.84萬元,若該訴訟結果不利於公司,可能加劇公司現金流壓力,存在資金鍊緊張的風險,如果法院採取保全措施,公司還存在資產或者銀行賬户被查封或者凍結的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.